-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

905.O2.6 905. Outcomes Research – Lymphoid Malignancies: Outcomes Research in Lymphoma/CLL: Biomarkers, Dosing Strategies, and Big-Data

Symposia: Outcomes Research—Lymphoid Malignancies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical Research, health outcomes research
Saturday, December 9, 2023: 2:00 PM-3:30 PM
Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
Moderators:
David A Russler-Germain, MD, PhD, BS, Washington University School of Medicine and Miguel Arturo Pavlovsky, MD, FUNDALEU
Disclosures:
Russler-Germain: Genentech: Research Funding.
This oral session will include oral abstracts in the lymphoid malignancies space, including provocative data on ibrutinib dosing strategies for CLL, real-world data on tafasitamab, and data on Ki-67 in marginal zone lymphoma.
2:00 PM

Kimberly Saverno, PhD1*, Kristin M. Zimmerman Savill2*, Bruce Feinberg2, John Galvin1, Prathamesh Pathak2*, Sarah Gordon2*, Theresa Amoloja1*, Mae Llorente1*, Narendranath Epperla, MD, MS3 and Loretta J. Nastoupil, MD4

1Incyte Corporation, Wilmington, DE
2Cardinal Health, Dublin, OH
3The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
4Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

2:15 PM

Narendranath Epperla, MD, MS1, Natalie S. Grover, MD2, Kaitlin Annunzio, DO3, Marcus P Watkins, PhD4*, Pallawi Torka, MD5, Reem Karmali, MD, MSc6, Andrea Carolina Anampa-Guzmán, MD7*, Timothy S. Oh, MD8*, Heather Reves, MS, BS9*, Montreh Tavakkoli, MD10, Emily Hansinger11*, Beth Christian, MD3, Colin Thomas, MD11, Stefan K. Barta, MD12, Praveen Ramakrishnan Geethakumari, MD, MS13, Nancy L. Bartlett, MD4, Geoffrey P. Shouse, PhD, DO14 and Adam J Olszewski, MD15

1The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH
2Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
3The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
4Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
5Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
6Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL
7Roswell Park Comprehensive Cancer Center, Buffalo, NY
8Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
9Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
10Department of Medicine, Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
11Thomas Jefferson University Hospital, Philadelphia, PA
12Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
13Section of Hematological Malignancies and Cellular Therapy, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
14City of Hope Comprehensive Cancer Center, Duarte, CA
15Brown University, Providence, RI

2:30 PM

Anna Torrent1*, Mireia Morgades2*, Gloria Iacoboni, MD3*, Juan Luis Reguera, MD4*, Mi Kwon5, Lucia Lopez Corral, MD, PhD6*, Rafael Hernani7*, Valentin Ortiz-Maldonado, MD8*, Jaime Sanz, MD, PhD9*, Ana Carolina Caballero Gonzalez10*, Luisa Guerra11*, Jose Maria Sanchez Pina12*, Alberto Mussetti13*, Alejandro Martin Garcia-Sancho, MD14*, Mariana Bastos-Oreiro, MD15*, Javier Delgado, MD4*, Cecilia Carpio16*, Juan-Manuel Sancho, MD, PhD17*, Antonio Perez Martinez, MD, PhD18* and Pere Barba, MD19

1Institut Català D'oncologia-Hospital Germans Trias I Pujol. Josep Carrera, Badalona, ESP
2ICO-Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras (IJC), Universitat Autònoma de Barcelona, Badalona, Spain
3Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, SEATTLE, WA
4University Hospital Virgen del Rocío, Sevilla, Spain
5General University Hospital Gregorio Marañón, Madrid, Spain
6Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Hospital Universitario de Salamanca, Salamanca, Spain
7Clinical Univesity Hospital of Valencia, Valencia, Spain
8Hospital Clinic, Barcelona, Spain
9Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, España, Valencia, Spain
10Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain
11Sevicio de Hematología, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain
12Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
13Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
14Department of Hematology, Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain
15Hematology Department, Hospital General Gregorio Marañon, Madrid, ESP
16Vall D' Hebron Hospital, Barcelona, Spain
17Hematology Department, ICO Badalona, Germans Trias i Pujol University Hospital. Universitat Autònoma de Barcelona. Josep Carreras Leukemia Research Institute, Barcelona, Spain
18Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain
19Deparment of Hematology, Vall Hebron Institute of Oncology (VHIO), Hospital Universitari Vall D'Hebron, La Garriga, Barcelona, Spain

2:45 PM

Shruti Gupta, MD, MPH1*, Ann LaCasce, MD2, Rebecca Karp Leaf, MD3, Sarah Kaunfer1* and David E Leaf, MD, MMSc1*

1Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3Massachusetts General Hospital, Boston, MA

3:00 PM

Mazyar Shadman, MD, MPH1, Sudeep Karve, PhD2*, Sima Patel, PhD2*, Andrew Rava, MPH3*, Haiyan Sun, MS3*, Amanda Howarth, MPH3*, Samantha Tomicki, MPH3*, Bhavini P. Srivastava, MSc2* and Deborah M. Stephens, DO4

1Fred Hutchinson Cancer Center, Seattle, WA
2AbbVie, North Chicago, IL
3Genesis Research, Hoboken, NJ
4Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

3:15 PM

Nilanjan Ghosh, MD, PhD1, Ruibin Wang, PhD2*, Zhijie Ding, PhD3*, Jinghua He, PhD, MPH2*, Alex Bokun, PharmD3*, Heena Mavani, PharmD, MBA3*, Zaina P Qureshi, PhD, MS, MPH3* and Kerry A Rogers, MD4

1Atrium Health Levine Cancer Institute, Charlotte, NC
2Janssen Scientific Affairs, LLC, Titusville, NJ
3Janssen Scientific Affairs, LLC, Horsham, PA
4Division of Hematology, The Ohio State University, Columbus, OH

*signifies non-member of ASH